JANSSEN RESEARCH & DEVELOPMENT, LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Active Crohn's Disease or Ulcerative Colitis

Phase 1

Suspended

Conditions: Crohn Disease
Ulcerative Colitis

Interventions: Drug: Midazolam 2 mg
Drug: Ustekinumab IV Infusion
Drug: Ustekinumab SC Injection
Drug: Warfarin 10 mg
Drug: Vitamin K 10 mg
Drug: Dextromethorphan 30 mg
Drug: Omeprazole 20 mg
Drug: Caffeine 100 mg

First Posted Date: 2017-12-02

Last Posted Date: 2024-06-21

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 57

Registration Number: NCT03358706

Locations: 🇧🇪
Ghent University Hospital, Gent, Belgium
🇧🇪
Az Sint-Maarten, Mechelen, Belgium
🇬🇧
Royal Liverpool University Hospital, Liverpool, United Kingdom

and more 13 locations

A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple Myeloma

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Daratumumab
Drug: JNJ-63723283

First Posted Date: 2017-11-30

Last Posted Date: 2022-12-05

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 10

Registration Number: NCT03357952

Locations: 🇧🇪
Algemeen Ziekenhuis Klina, Brasschaat, Belgium
🇮🇱
Hadassah Medical Center, Jerusalem, Israel
🇧🇪
UZBrussel, Brussel, Belgium

and more 10 locations

A Study of Paliperidone Palmitate 6-Month Formulation

Phase 3

Completed

Conditions: Schizophrenia

Interventions: Drug: PP1M
Drug: PP6M
Drug: PP3M 350 mg eq.
Other: Placebo
Drug: PP3M 525 mg eq.

First Posted Date: 2017-11-17

Last Posted Date: 2023-09-15

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 841

Registration Number: NCT03345342

Locations: 🇺🇸
New Life Medical Research Center, Inc., Hialeah, Florida, United States
🇺🇸
Atlanta Center for Medical Research, Atlanta, Georgia, United States
🇺🇸
Clintex Research Group, Miami, Florida, United States

and more 135 locations

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of JNJ-64991524 in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: JNJ-64991524 Dose Level 2
Drug: JNJ-64991524 Dose Level 6
Drug: JNJ-64991524 Dose Level 3
Drug: JNJ-64991524 Dose Level 4
Drug: JNJ-64991524 Dose Level 5
Drug: JNJ-64991524 Dose Level 1
Drug: Placebo
Drug: JNJ-64991524 Dose Level 9
Drug: JNJ-64991524 Dose Level 7
Drug: JNJ-64991524 Dose Level 8

First Posted Date: 2017-11-17

Last Posted Date: 2019-01-24

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 86

Registration Number: NCT03346122

Locations: 🇧🇪
SGS Clinical Pharmacology Unit (located in ZNA Stuivenberg), Antwerpen, Belgium

A Long-term Follow-up Study to Evaluate the Impact of Lumicitabine on the Incidence of Asthma and/or Wheezing in Infants and Children With a History of Respiratory Syncytial Virus Infection

Phase 2

Completed

Conditions: Respiratory Syncytial Virus Infections

Interventions: Drug: Placebo
Drug: Lumicitabine

First Posted Date: 2017-11-06

Last Posted Date: 2021-04-13

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 7

Registration Number: NCT03332459

Locations: 🇯🇵
National Hospital Organization Niigata National Hospital, Niigata, Japan
🇯🇵
Fukuyama City Hospital, Fukuyama, Japan
🇯🇵
National Hospital Organization Beppu Medical Center, Oita, Japan

and more 1 locations

A Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine (JNJ-64041575) Regimens in Hospitalized Infants and Children Aged 28 Days to 36 Months Infected With Respiratory Syncytial Virus

Phase 2

Terminated

Conditions: Respiratory Syncytial Viruses

Interventions: Drug: Placebo
Drug: Lumicitabine

First Posted Date: 2017-11-06

Last Posted Date: 2019-12-23

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 7

Registration Number: NCT03333317

Locations: 🇯🇵
Takatsuki General Hospital, Osaka, Japan
🇯🇵
Shikoku Medical Center for Children and Adults, Zentsuji, Japan
🇵🇱
Plejady Medical Center, Malopolska, Poland

and more 26 locations

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-54767414 (Daratumumab) in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: Daratumumab
Drug: rHuPH20

First Posted Date: 2017-10-25

Last Posted Date: 2019-09-06

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 66

Registration Number: NCT03320707

Locations: 🇺🇸
Celerion, Tempe, Arizona, United States

A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy

Phase 2

Completed

Conditions: Depressive Disorder, Major

Interventions: Drug: Quetiapine XR
Drug: JNJ-42847922
Drug: Placebo Matching to JNJ-42847922
Drug: Placebo Matching to Quetiapine XR
Drug: Selective Serotonin Reuptake Inhibitor (SSRI)
Drug: Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)

First Posted Date: 2017-10-25

Last Posted Date: 2023-05-03

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 107

Registration Number: NCT03321526

Locations: 🇺🇸
Hapworth Psychiatric Medical PLLC, New York, New York, United States
🇺🇸
Suburban Clinical Research Group, Inc, Bolingbrook, Illinois, United States
🇺🇸
Ericksen Research and Development, Clinton, Utah, United States

and more 47 locations

A Study to Evaluate the Effect of Ibrutinib on the Pharmacokinetics of Oral Contraceptives, CYP2B6, and CYP3A4 Substrates in Female Participants With B Cell Malignancy

Phase 1

Completed

Conditions: Leukemia, Lymphocytic, Chronic, B-Cell

Interventions: Drug: Ibrutinib
Drug: Bupropion
Drug: Midazolam

First Posted Date: 2017-10-04

Last Posted Date: 2019-12-05

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 25

Registration Number: NCT03301207

Locations: 🇪🇸
Hosp. Univ. Fund. Jimenez Diaz, Madrid, Spain
🇵🇱
Pratia MCM Krakow, Krakow, Poland
🇵🇱
Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wroclawiu, Wroclaw, Poland

and more 1 locations

A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma

Phase 3

Active, not recruiting

Conditions: Smoldering Multiple Myeloma

First Posted Date: 2017-10-04

Last Posted Date: 2025-01-09

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 390

Registration Number: NCT03301220

Locations: 🇨🇦
Arthur J E Child Comprehensive Cancer Centre, Calgary, Alberta, Canada
🇺🇸
Arizona Oncology Associates, PC - HAL, Phoenix, Arizona, United States
🇺🇸
Innovative Clinical Research Inc, Whittier, California, United States

and more 159 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy